Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Prostatic Neoplasms 86Lung Neoplasms 64Carcinoma, Non-Small-Cell Lung 50Neoplasm Metastasis 48Breast Neoplasms 48Glioma 41Glioblastoma 38Pancreatic Neoplasms 35Multiple Myeloma 35Brain Neoplasms 34Carcinoma, Renal Cell 33Lymphoma, Large B-Cell, Diffuse 29Melanoma 28Urinary Bladder Neoplasms 27Colorectal Neoplasms 27Squamous Cell Carcinoma of Head and Neck 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 21Oropharyngeal Neoplasms 21Carcinoma, Hepatocellular 21Lymphoma 20Mouth Neoplasms 18Lymphoma, Follicular 18Sarcoma 17Fallopian Tube Neoplasms 16Carcinoma, Transitional Cell 16Carcinoma 16Laryngeal Neoplasms 15Astrocytoma 15Lymphoma, Mantle-Cell 14

Interventions

Fluorouracil 16Oxaliplatin 14Nivolumab 14Leucovorin 13pembrolizumab 9Paclitaxel 9Capecitabine 9Radiotherapy 6Radiation 6durvalumab 5Taxes 5Irinotecan 5Cisplatin 5Trastuzumab 4Specimen Handling 4Drug Therapy 4Carboplatin 4tremelimumab 3dehydroftorafur 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Endoscopy 3Docetaxel 3Biopsy 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2tislelizumab 2futibatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Magnetic Resonance Spectroscopy × 1 year × Clear all
NCT06203600 2026-05-26

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT05677490 2026-05-08

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
382 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡